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Introduction {#sec001}
============

Cardiovascular diseases remain the leading cause of mortality in both men and women globally \[[@pone.0232507.ref001]\], despite the conventional dogma that women are more protected against cardiovascular diseases than men. Indeed, the incidence of cardiovascular diseases in post-menopausal women is equal to those in age-matched men \[[@pone.0232507.ref002]\]. Furthermore, there are a number of cardiovascular diseases that are more prevalent in women than in men, including Takotsubo cardiomyopathy \[[@pone.0232507.ref003], [@pone.0232507.ref004]\] and microvascular angina \[[@pone.0232507.ref005]\]. Importantly, there are marked sex differences in the pathogenesis and/or clinical presentation of several cardiovascular diseases \[[@pone.0232507.ref006]\]. For instance, despite similar overall risk of heart failure between men and women, heart failure with reduced ejection fraction (HFrEF) is more prevalent in men, while heart failure with preserved ejection fraction (HFpEF) is more prevalent in women \[[@pone.0232507.ref006], [@pone.0232507.ref007]\]. Although the rationale for the higher prevalence of these specific conditions in women is still not fully understood, coronary microvascular dysfunction and endothelial inflammation have been suggested to play key roles \[[@pone.0232507.ref006]\].

The conventional view is that sex-related differences in cardiovascular diseases are mainly attributed to male and female sex hormones \[[@pone.0232507.ref002]\]. Traditionally, estrogen has been thought to provide a protective effect, whereas testosterone has a detrimental cardiovascular effect \[[@pone.0232507.ref002]\]. Although this traditional view has offered the biological underpinning for several cardiovascular pathologies that are more prevalent and more severe in males \[[@pone.0232507.ref008], [@pone.0232507.ref009]\], it could not explain other clinical and preclinical observations including: the worse outcome of post-menopausal women receiving supplemental estrogen therapy which was mainly attributed to increased rate of thromboembolic events \[[@pone.0232507.ref010]\], in addition to post-ischemic cardioprotection in aromatase knock-out mice \[[@pone.0232507.ref011]\] and worsening of heart failure in castrated male experimental animals \[[@pone.0232507.ref012], [@pone.0232507.ref013]\] which suggest a cardioprotective role of androgens. In addition to sex hormones, recent studies suggest that inherent differences in sex chromosome genes may contribute to sex differences in cardiovascular diseases \[[@pone.0232507.ref014]\]. These studies, among others, strongly suggest that sexual dimorphism in cardiovascular diseases is highly complex in humans (reviewed in \[[@pone.0232507.ref006], [@pone.0232507.ref008], [@pone.0232507.ref014]--[@pone.0232507.ref016]\]) and thus warrants further investigations in a variety of models in laboratory animals.

Isoproterenol is non-selective beta-adrenergic agonist commonly used as a pharmacological agent to induce a spectrum of cardiac pathologies in laboratory animal models. A number of studies determined the sex-related differences in the phenotypic manifestations and molecular determinants in models of isoproterenol-induced cardiac hypertrophy with discrepant results. While some of these studies reported that female experimental animals were protected against cardiac hypertrophy and fibrosis in response to chronic administration of low isoproterenol doses (0.04 mg/kg/day for 6 months) \[[@pone.0232507.ref017], [@pone.0232507.ref018]\], other studies reported no difference in cardiac hypertrophy in response to a higher dose (30 mg/kg/day for 7 days) \[[@pone.0232507.ref019]\], and one study showed that female rats were more sensitive than males to cardiac fibrosis induced by moderate doses of isoproterenol (7.5 mg/kg/day for 3 weeks) \[[@pone.0232507.ref020]\]. These studies suggest that sex-related differences in the response to isoproterenol are dose-dependent. Since most of the previous work has focused on determining sex-related differences in isoproterenol-induced cardiac hypertrophy and fibrosis \[[@pone.0232507.ref017]--[@pone.0232507.ref020]\], in the current work, we comprehensively investigated key echocardiographic, molecular, and histopathologic sex differences in a model of cardiac dysfunction produced by prolonged administration of moderate doses of isoproterenol (10 mg/kg/day for 14 days) in male and female C57Bl/6NCrl mice.

Methods {#sec002}
=======

Animals {#sec003}
-------

Animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Minnesota (Protocol ID: 1807-36187A). Intact male (*n* = 19) and female (*n* = 19) C57Bl/6NCrl mice were purchased from Charles River Laboratories. All mice were housed in groups of 3--4 mice per cage and maintained under standard specific pathogen free (SPF) conditions. Mice were given food and water ad libitum in a 12 h light/12 h dark cycle at 21 ± 2 °C. Starting at 15 weeks of age, 10 mg/kg isoproterenol (*n* = 12 male, *n* = 12 female) or an equivalent volume of sterile saline (*n* = 7 male, *n* = 7 female) was administered by subcutaneous daily injection for 14 days. Age-matched mice that had been castrated (*n* = 4), ovariectomized (*n* = 4), or sham-operated (*n* = 4 male, *n* = 4 female) by Charles River Laboratories at the age of 4 weeks were subjected to the isoproterenol regimen described above. Mice were monitored for 30 minutes after each isoproterenol injection, and once daily during the prolonged administration to make sure that this dosage regimen is well tolerated. No mortality or significant morbidity were observed in all experimental groups. Animals were humanely euthanized by decapitation under isoflurane anesthesia 1 day after the last injection of isoproterenol. Hearts were collected, rinsed in ice-cold phosphate-buffered saline, snap frozen in liquid nitrogen, and stored at -80°C.

Echocardiography {#sec004}
----------------

Cardiac function was assessed by echocardiography prior to isoproterenol administration and immediately following the first dose to determine whether there is a sex difference in the inotropic or chronotropic response to acute isoproterenol administration (n = 6 per sex). To determine the response to prolonged isoproterenol administration, cardiac function was assessed by echocardiography following the last dose of isoproterenol or sterile saline injections (n = 7--12 per sex per group). Echocardiography was performed using the Vevo 2100 system (VisualSonics, Inc., Toronto, Ontario, Canada) equipped with an MS400 transducer. Anesthesia was induced with 3% isoflurane in oxygen and maintained at 1--2% during the procedure. Mice were secured in a supine position on a heated physiologic monitoring stage. Parasternal short axis images of the left ventricle were obtained in M-Mode at the level of the papillary muscles. Endocardial and epicardial borders were manually traced over 3--4 cardiac cycles and cardiac output, ejection fraction, fractional shortening, end diastolic and systolic volumes, and left ventricular (LV) Mass were calculated using VisualSonics cardiac measurement package of the Vevo 2100.

Histopathology {#sec005}
--------------

LV heart sections were collected, fixed in 10% neutral buffered formalin and embedded in paraffin. Four-micron sections were stained with hematoxylin and eosin (HE) or Masson's trichrome stain. Histopathologic evaluation was performed by a board-certified veterinary pathologist who was blinded to the experimental group. Each stained HE stained section was examined for (a) inflammation (distribution, severity, and cell type), (b) vascular pathology, (c) interstitial fibrosis, and (d) myofiber degeneration/vacuolization. Inflammation and fibrosis were assessed as follows: 0, absent; 1, minimal inflammation or fibrosis; 2, mild inflammation or fibrosis; 3, moderate inflammation or fibrosis; and 4, marked inflammation or fibrosis. For vascular and myofiber pathology, sections were scored based upon the severity of the change (minimal, mild, moderate, or severe) and the morphologic nature of the pathology. The severity of fibrosis on the trichrome stained section was assessed for fibrosis as described above. Sections from each heart were also immunohistochemically stained for expression of MAC-2 (galectin-3). In brief, four-micron sections were dewaxed and rehydrated prior to antigen retrieval. Thereafter, sections were incubated with either anti-galectin-3 antibody (clone M3/38, Cedarlane Labs, Burlington, NC) according to manufacturer's instruction. The number of MAC-2 positive cells was manually quantified on the five most cellular 200X images.

RNA extraction {#sec006}
--------------

Total RNA was extracted from 20 mg frozen heart tissue using 300 μL Trizol reagent (Life Technologies, Carlsbad, CA) according to manufacturer's instructions. RNA concentrations were attained by measuring absorbance at 260 nm using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) and first-strand cDNA was synthesized from 1.5 μg total RNA using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) according to manufacturer's instructions.

Real-time PCR {#sec007}
-------------

Specific mRNA expression was quantified by SYBR Green (Applied Biosystems) based real-time PCR performed on an ABI 7900HT instrument (Applied Biosystems) using 384-well optical reaction plates. Thermocycler conditions were as follows: 95°C for 10 min, followed by 40 PCR cycles of denaturation at 95°C for 15 sec, and annealing/extension at 60°C for 1 min. Gene expression was determined using previously published primers for *ANP*, *BNP*, *and TGF-beta1*. Primer sequences are listed in [S1 Table](#pone.0232507.s001){ref-type="supplementary-material"}. The mRNA expression levels were normalized to *β-actin* and are expressed relative to male control. Relative gene expression was determined by the ΔΔCT method. Primer specificity and purity of the final PCR product were verified by melting curve analysis.

Statistical analysis {#sec008}
--------------------

Data were analyzed using GraphPad Prism software (version 7.01, La Jolla, CA) and are presented as means ± standard errors of the mean (SEM). Comparisons among different sex or surgical alterations and treatment groups were performed by ordinary two-way analysis of variance (ANOVA), followed by Tukey's multiple comparison post-hoc analysis or two-way ANOVA (repeated measures), followed by Sidak's post-hoc analysis where appropriate. Statistical analysis for histopathologic grading and MAC-2 staining was performed using the non-parametric Kruskal-Wallis test. A *p* value of \< 0.05 was taken to indicate statistical significance.

Results {#sec009}
=======

Acute effects of isoproterenol administration on echocardiographic parameters in intact male and female mice {#sec010}
------------------------------------------------------------------------------------------------------------

Cardiac function was assessed by echocardiography prior to and immediately following a single subcutaneous injection of 10 mg/kg isoproterenol in adult male and female mice. Representative echocardiographic images obtained in M-Mode from each group are displayed in [Fig 1A](#pone.0232507.g001){ref-type="fig"}. Acute administration of isoproterenol had a similar effect on cardiac function in males and females. Ejection fraction and fractional shortening were significantly increased to a similar degree in both sexes. Ejection fraction was increased by 53% in males and 59% in females ([Fig 1B](#pone.0232507.g001){ref-type="fig"}) and a 110% increase in fractional shortening was evident in both sexes ([Fig 1C](#pone.0232507.g001){ref-type="fig"}). End-systolic volume was decreased by 90% in both sexes ([Fig 1D](#pone.0232507.g001){ref-type="fig"}) and end-diastolic volumes were down 35% in male and 30% in female mice ([Fig 1E](#pone.0232507.g001){ref-type="fig"}). Cardiac output was significantly increased (35%) in female mice and 20% in male mice, though this increase did not reach statistical significance in males ([Fig 1F](#pone.0232507.g001){ref-type="fig"}). As expected, acute treatment with isoproterenol induced a significant increase in heart rate by 22% in male and 13% in female mice ([Fig 1G](#pone.0232507.g001){ref-type="fig"}). Matched two-way ANOVA revealed a significant effect of isoproterenol on all the measured parameters, while sex effect was significant only on the cardiac output. There was no significant interaction between isoproterenol and sex in all the measured parameters ([S2 Table](#pone.0232507.s002){ref-type="supplementary-material"}).

![Acute administration of isoproterenol causes a similar cardiac response in male and female mice.\
Cardiac function in adult male (*n* = 6) and female (*n* = 6) C57Bl/6NCrl mice was assessed by trans-thoracic echocardiography just prior to and immediately following a single subcutaneous injection of 10 mg/kg isoproterenol (ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) heart rate. Values are shown as means ± SEM. \**p*\<0.05, compared to before treatment of the same sex by matched two-way ANOVA with Sidak's post-hoc analysis.](pone.0232507.g001){#pone.0232507.g001}

Chronic administration of isoproterenol caused significant cardiac dysfunction and hypertrophy in intact male and female mice {#sec011}
-----------------------------------------------------------------------------------------------------------------------------

Cardiac function in male and female mice was assessed by echocardiography following 14 days of treatment with isoproterenol or saline (control). Representative echocardiographic images obtained in M-Mode from each group are displayed in [Fig 2A](#pone.0232507.g002){ref-type="fig"}. Chronic administration of isoproterenol had a similar effect on cardiac function in male and female mice. Ejection fraction, an accurate measure of systolic dysfunction \[[@pone.0232507.ref021]\], and fractional shortening were significantly decreased to a similar degree in both sexes when compared to saline treatment of the same sex. Ejection fraction was decreased by 25% in male and 21% in female mice ([Fig 2B](#pone.0232507.g002){ref-type="fig"}). Fractional shortening was decreased by 30% in males and 24% in females ([Fig 2C](#pone.0232507.g002){ref-type="fig"}). End-systolic and diastolic volumes were significantly increased in male (87% and 20%, respectively), but not female mice ([Fig 2D and 2E](#pone.0232507.g002){ref-type="fig"}). Although not significant, a 61% increase in end-systolic volume was evident in female mice, ([Fig 2D](#pone.0232507.g002){ref-type="fig"}) with little change in end-diastolic volume ([Fig 2E](#pone.0232507.g002){ref-type="fig"}). Cardiac output was decreased by 22% in male mice and 19% in female mice, though this decrease did not reach significance in female mice ([Fig 2F](#pone.0232507.g002){ref-type="fig"}). Female mice had significantly smaller hearts than male mice from the same treatment group ([Fig 2G--2H](#pone.0232507.g002){ref-type="fig"}). Isoproterenol-treated mice exhibited a significantly higher heart weight/tibia length ratio (HW/TL) compared to saline-treated mice ([Fig 2G](#pone.0232507.g002){ref-type="fig"}). Two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters, while sex effect was significant only in LV Mass and the heart weight/tibia length ratio (HW/TL). There was no significant interaction between isoproterenol and sex in any of the measured parameters ([S3 Table](#pone.0232507.s003){ref-type="supplementary-material"}).

![Prolonged administration of isoproterenol causes similar cardiac dysfunction in male and female mice.\
Male and female C57Bl/6NCrl mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female *n* = 12) or saline (male, female *n* = 7) daily for 14 days. (A-F) Cardiac function was assessed by trans-thoracic echocardiography. (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. (H) Heart weight to tibial length ratio. Values are shown as means ± SEM. \**p*\<0.05, compared to control treatment of the same sex; \# *p*\<0.05, compared to male of same treatment by two-way ANOVA with Tukey's post-hoc analysis.](pone.0232507.g002){#pone.0232507.g002}

Chronic administration of isoproterenol caused significant pathological lesions in the hearts of intact male and female mice {#sec012}
----------------------------------------------------------------------------------------------------------------------------

Analysis of the HE- and trichrome-stained heart sections revealed increased fibrosis in both isoproterenol-treated male and female mice (Figs [3](#pone.0232507.g003){ref-type="fig"} and [4A](#pone.0232507.g004){ref-type="fig"}). The severity of fibrosis did not significantly differ between the male and female mice. Similarly, both male and female treated mice demonstrated significantly higher numbers of MAC-2 positive cells than their control counterparts but were not significantly different from each other (Figs [3](#pone.0232507.g003){ref-type="fig"} and [4B](#pone.0232507.g004){ref-type="fig"}).

![Prolonged administration of isoproterenol causes similar histopathologic changes in hearts of male and female mice.\
Male and female C57Bl/6NCrl mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female *n* = 6, 5, respectively) or saline (male, female *n* = 5) daily for 14 days. Fig 3 shows representative images from hematoxylin and eosin (HE), Masson's trichrome, and MAC-2 stained sections.](pone.0232507.g003){#pone.0232507.g003}

![Prolonged administration of isoproterenol causes similar levels of fibrosis and MAC-2 accumulation in hearts of male and female mice.\
Male and female C57Bl/6NCrl mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female n = 6, 5, respectively) or saline (male, female n = 5) daily for 14 days. (A) Isoproterenol treated male and female C57Bl/6NCrl mice demonstrate increased collagen (light blue, Masson's trichrome) deposition and (B) increased numbers of MAC-2 positive cells compared to control mice. \**p\<0*.*05*, compared to control treatment of the same sex, by non-parametric Kruskal-Wallis test.](pone.0232507.g004){#pone.0232507.g004}

Chronic administration of isoproterenol induced the gene expression of markers of cardiac remodeling and fibrosis in intact male and female mice {#sec013}
------------------------------------------------------------------------------------------------------------------------------------------------

The mRNA expression levels of the natriuretic peptides ANP and BNP were increased, though not significantly, in hearts of mice treated with isoproterenol for 14 days ([Fig 5A and 5B](#pone.0232507.g005){ref-type="fig"}). Similar changes were observed in male and female mice in both ANP (2.5- and 3-fold, respectively) ([Fig 5A](#pone.0232507.g005){ref-type="fig"}) and BNP (3- and 3.8-fold, respectively) ([Fig 5B](#pone.0232507.g005){ref-type="fig"}). Gene expression of the fibrotic marker TGF-beta1 was significantly induced following isoproterenol treatment. A significant 2-fold increase in the gene expression of TGF-beta1 was observed in both male and female mice ([Fig 5C](#pone.0232507.g005){ref-type="fig"}). Prolonged isoproterenol administration for 14 days had a significant effect on all the measured genes, while neither sex effect nor the interaction between sex and isoproterenol were statistically significant ([S4 Table](#pone.0232507.s004){ref-type="supplementary-material"}).

![Prolonged administration of isoproterenol causes similar changes in gene expression of the natriuretic peptides and fibrotic markers in hearts of male and female mice.\
Male and female C57Bl/6NCrl mice were given subcutaneous injections of 10 mg/kg isoproterenol (ISO) or saline (control) daily for 14 days (*n* = 5--6 per group). mRNA expression of (A) ANP, (B) BNP, (C) TGF-beta1 mouse hearts. Results are normalized to beta-actin and expressed relative to male control. Values are shown as means ± SEM. \*p\<0.05, compared to control treatment of the same sex.](pone.0232507.g005){#pone.0232507.g005}

Effect of castration of male mice on isoproterenol-induced cardiac dysfunction {#sec014}
------------------------------------------------------------------------------

Isoproterenol treatment for 14 days resulted in similar functional changes in sham and castrated mice. Representative echocardiographic images obtained in M-Mode from each group are displayed in [Fig 6A](#pone.0232507.g006){ref-type="fig"}. Ejection fraction ([Fig 6B](#pone.0232507.g006){ref-type="fig"}) and fractional shortening ([Fig 6C](#pone.0232507.g006){ref-type="fig"}) were significantly reduced by approximately 20% in both sham and castrated mice. Significant increases in end-systolic volumes ([Fig 6D](#pone.0232507.g006){ref-type="fig"}) were clearly evident in sham and castrated mice (35 and 56%, respectively). End-diastolic volumes ([Fig 6E](#pone.0232507.g006){ref-type="fig"}) were also increased in sham and castrated mice (9 and 15%, respectively), though the increase in sham mice was not statistically significant. Similar decreases in cardiac output ([Fig 6F](#pone.0232507.g006){ref-type="fig"}) were observed in castrated and sham mice, though this decrease was not significant in sham animals. Isoproterenol administration caused a significant increase in LV mass in both sham and castrated mice ([Fig 6G](#pone.0232507.g006){ref-type="fig"}). Matched two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters. However, the castration effect and the interaction between isoproterenol and castration were not statistically significant ([S5 Table](#pone.0232507.s005){ref-type="supplementary-material"}).

![Prolonged administration of isoproterenol causes similar cardiac dysfunction in castrated or sham-operated (SHAM) male mice.\
(A-F) Cardiac function in adult male castrated (*n* = 4) and sham-operated (*n* = 4) C57Bl/6NCrl mice was assessed by trans-thoracic echocardiography one week prior to treatment (Pre-ISO), and again after 2 weeks of daily subcutaneous injections of 10 mg/kg isoproterenol (Post-ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. \**p*\<0.05, compared to before treatment of the same surgical status by matched two-way ANOVA with Sidak's post-hoc analysis.](pone.0232507.g006){#pone.0232507.g006}

Effect of ovariectomy of female mice on isoproterenol-induced cardiac dysfunction {#sec015}
---------------------------------------------------------------------------------

Isoproterenol treatment for 14 days resulted in similar functional changes in sham and ovariectomized mice when compared to measures obtained prior to treatment. Representative echocardiographic images obtained in M-Mode from each group are displayed in [Fig 7A](#pone.0232507.g007){ref-type="fig"}. Ejection fraction and fractional shortening were significantly decreased following isoproterenol treatment in sham (23% and 28%, respectively) and ovariectomized (35% and 42% respectively) mice ([Fig 7B and 7C](#pone.0232507.g007){ref-type="fig"}). Isoproterenol treatment resulted in significantly greater end-systolic and diastolic volumes in both sham (99% and 46%, respectively) and ovariectomized (128% and 31%, respectively) mice ([Fig 7D and 7E](#pone.0232507.g007){ref-type="fig"}). Cardiac output was unaltered by isoproterenol treatment in the sham group but was significantly reduced by 20% in ovariectomized mice ([Fig 7F](#pone.0232507.g007){ref-type="fig"}). Isoproterenol administration caused a significant increase in LV mass in both sham and ovariectomized mice ([Fig 7G](#pone.0232507.g007){ref-type="fig"}). Matched two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters except the cardiac output. However, the ovariectomy effect and the interaction between isoproterenol and ovariectomy were not statistically significant except the cardiac output, where there was a significant interaction ([S6 Table](#pone.0232507.s006){ref-type="supplementary-material"}).

![Prolonged administration of isoproterenol causes similar cardiac dysfunction in ovariectomized (OVX) or sham-operated (SHAM) female mice.\
(A-F) Cardiac function in adult female ovariectomized (OVX) (*n* = 3) and sham-operated (*n* = 4) C57Bl/6NCrl mice was assessed by trans-thoracic echocardiography one week prior to treatment (Pre-ISO), and again after 2 weeks of daily subcutaneous injections of 10 mg/kg isoproterenol (Post-ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. \**p*\<0.05, compared to before treatment of the same surgical status by matched two-way ANOVA with Sidak's post-hoc analysis.](pone.0232507.g007){#pone.0232507.g007}

Discussion {#sec016}
==========

Sex-related differences have been described in several animal models of cardiac hypertrophy/dysfunction. In models of doxorubicin-induced cardiotoxicity, we and others have demonstrated a profound sexual dimorphism with female rodents being much less sensitive to doxorubicin than male rodents \[[@pone.0232507.ref022]--[@pone.0232507.ref024]\]. Similarly, female mice were protected against iron overload-induced cardiomyopathy \[[@pone.0232507.ref025]\]. On the other hand, both male and female rats developed cardiac hypertrophy at 4 and 16 weeks of chronic volume overload. Interestingly, the increase in cardiac muscle mass was greater in females than males at 16 weeks. At 4 weeks of chronic volume overload, however, a decrease in fractional shortening occurred in males only \[[@pone.0232507.ref026]\]. Pressure overload has been shown to increase left ventricular mass to the same extent in male and female rodents, but with a more marked decline in cardiac function in males \[[@pone.0232507.ref027], [@pone.0232507.ref028]\]. These studies clearly demonstrate that sex-related differences are model-specific.

Isoproterenol-induced cardiac dysfunction is an established model of excessive catecholamine-induced cardiovascular disease \[[@pone.0232507.ref029]--[@pone.0232507.ref031]\]. While low doses of isoproterenol (0.04 mg/kg/day for 6 months) cause cardiac hypertrophy and fibrosis without significant cardiac dysfunction \[[@pone.0232507.ref017], [@pone.0232507.ref018]\], moderate doses (4--60 mg/kg/day) induce cardiac dysfunction and heart failure \[[@pone.0232507.ref029], [@pone.0232507.ref032]--[@pone.0232507.ref034]\] and high doses (150--300 mg/kg/day) induce a model of myocardial infarction \[[@pone.0232507.ref033], [@pone.0232507.ref035]\]. We selected a moderate dose of isoproterenol (10 mg/kg/day) in our current study because sex-related differences in the response to the low dose have been previously determined \[[@pone.0232507.ref017], [@pone.0232507.ref018]\] and we expected the high dose to cause severe injury that would mask any potential sex-related difference. Therefore, in the current work, we investigated key sex-related differences in the acute response to a moderate isoproterenol dose as well as the response to prolonged administration of isoproterenol (10 mg/kg/day) for 2 weeks to C57Bl/6NCrl mice. After acute administration of isoproterenol, we found out that there was a similar increase in cardiac function parameters such as ejection fraction and fractional shortening as well as a similar increase in heart rates in both male and female mice, indicating similar inotropic and chronotropic effects of isoproterenol in male and female mice. In agreement with these findings, isoproterenol induced similar acute hemodynamic changes in male and female CD-1 mice \[[@pone.0232507.ref020]\]. Isolated adult rat hearts showed similar chronotropic and inotropic responses to isoproterenol \[[@pone.0232507.ref036]\]. Male sex was associated with blunted β-adrenergic receptor responsiveness to isoproterenol injection in human volunteers \[[@pone.0232507.ref037]\]. Contrariwise, cardiomyocytes isolated from male rats had an augmented beta-adrenergic response to isoproterenol \[[@pone.0232507.ref038]\]. These discrepancies may have arisen due to differences between the *in vivo* and *in vitro* models employed in these studies.

We have also determined the response to prolonged isoproterenol administration in male and female mice. In agreement with human studies \[[@pone.0232507.ref039], [@pone.0232507.ref040]\], the LV mass, the heart weight, and absolute cardiac output values were lower in female than in male mice. However, our data demonstrate that prolonged isoproterenol administration caused a similar extent of cardiac hypertrophy and cardiac dysfunction in both male and female mice. Continuous isoproterenol administration by mini-osmotic pumps (30 mg/kg/day) to C57Bl/6J mice for one week caused cardiac hypertrophy in both male and female mice; however, females developed significantly less hypertrophy than males \[[@pone.0232507.ref041]\]. Importantly, this regimen increased fractional shortening in males, but not in female mice \[[@pone.0232507.ref041]\]. Chronic administration of low isoproterenol doses (0.04 mg/kg/day for 6 months) from 9 to 15 months of age induced cardiac hypertrophy and dilation in male Spontaneously hypertensive rats (SHRs), but not in females \[[@pone.0232507.ref018]\]. At the molecular levels, we showed that prolonged isoproterenol administration induced the gene expression of the natriuretic peptides, ANP and BNP, to a similar extent in hearts of male and female mice.

In addition to cardiac dysfunction and hypertrophy, male and female C57Bl/6NCrl mice developed a similar degree of myocardial fibrosis in response to chronic isoproterenol administration. There are discrepant reports about the sex-dependent effect of chronic isoproterenol administration on cardiac fibrosis. On one hand, female CD-1 mice showed higher fibrosis than males after chronic isoproterenol administration 7.5 mg/kg/day for 3 weeks \[[@pone.0232507.ref020]\]. On the other hand, chronic isoproterenol administration 0.04 mg/kg/day for 6 months increased interstitial collagen in male SHRs, but not in females \[[@pone.0232507.ref018]\]. This discrepancy suggests that sex-related differences in the response to isoproterenol may be dose-dependent, with higher isoproterenol doses causing more severe damage that is not sexually dimorphic. It may also be attributed to strain difference, since male SHRs have a higher extent of baseline collagen content and cardiac hypertrophy than females \[[@pone.0232507.ref042]\]. In agreement with the similar effect on myocardial fibrosis, we also demonstrated that isoproterenol administration induced the gene expression of several fibrotic markers in hearts of male and female mice to a similar degree. We have also shown that MAC-2 positive cells were equally elevated in the hearts of male and female mice. MAC-2 expression has been shown to be highly associated with myocardial fibrosis \[[@pone.0232507.ref043], [@pone.0232507.ref044]\], although its causative role in inducing myocardial fibrosis is still controversial \[[@pone.0232507.ref045]\]. Although we did not observe significant differences in these key echocardiographic, histopathologic, and molecular markers of cardiac dysfunction, there may be sex-related differences in the molecular pathways leading to such outcome. This notion is supported by a recent study revealing sex-specific differences in cardiac proteomic and metabolomic profiles between men and women with a similar degree of human heart failure \[[@pone.0232507.ref046]\] and thus warrants further investigation.

In order to identify the potential role of male sex hormones, we determined the response to prolonged isoproterenol administration in castrated male mice compared to sham-operated animals. Intriguingly, there was no significant difference in the isoproterenol-induced cardiac dysfunction between castrated and sham-operated mice. In agreement with our results, castration had no effect on LV dilation produced by chronic isoproterenol administration 0.015 mg/kg/day for 6 months in Sprague Dawley rats \[[@pone.0232507.ref047]\]. In contrast, castration prevented cardiac hypertrophy, LV dilation, and increased interstitial collagen produced by chronic isoproterenol administration 0.04 mg/kg/day for 6 months male SHRs \[[@pone.0232507.ref017]\]. These effects may be attributed to the protective effect of castration on the underlying cardiovascular pathology in male SHR, as previously reported \[[@pone.0232507.ref048]\], rather than the response to isoproterenol.

In order to identify the role of female sex hormones, we studied the effects of isoproterenol administration in ovariectomized female mice compared to sham-operated controls. Similar to castration in male mice, ovariectomy had no significant effect on isoproterenol-induced cardiac dysfunction. Similar to our findings, ovariectomy did not change the response to chronic isoproterenol administration in female SHRs \[[@pone.0232507.ref017]\]. Contrariwise, ovariectomized rats developed more extensive cardiac remodeling than intact females in response to chronic volume overload \[[@pone.0232507.ref049]\]. Estrogen exerted concentration-dependent pro- and anti-hypertrophic response in cultured adult cardiomyocytes isolated from male and female rats \[[@pone.0232507.ref050]\]. Low estrogen concentrations 1 pM had a pro-hypertrophic effect, whereas high concentration 1 nM prevented phenylephrine-induced hypertrophy \[[@pone.0232507.ref050]\]. Estrogen has also been shown to exert a model-dependent effect. Estrogen prevented cardiac hypertrophy and dysfunction caused by pressure overload, but not by myocardial infarction \[[@pone.0232507.ref051]\]. Although the results of these gonadectomy experiments corroborated our previous findings in intact animals, the small sample size and the lack of saline-treated control mice are limitations to the current work. Therefore, future studies are planned to specifically determine the effects of gonadectomy on isoproterenol-induced cardiac dysfunction and remodeling and to identify the molecular determinants of these effects.

Conclusion {#sec017}
==========

The current study demonstrates lack of significant sex-related differences in cardiac hypertrophy, dysfunction, and fibrosis in response to moderate-dose isoproterenol (10 mg/kg/day for 14 days) in C57Bl/6NCrl mice. Our findings also demonstrate that gonadectomy of male and female mice did not have a significant impact on isoproterenol-induced cardiac dysfunction. This study suggests that female sex may not be sufficient to protect the heart in this model of isoproterenol-induced cardiac dysfunction. It also signifies the notion that sexual dimorphism in cardiovascular diseases is complex and highly model-dependent.

Supporting information {#sec018}
======================

###### Primer sequences used in this study.

(DOCX)

###### 

Click here for additional data file.

###### Two-way ANOVA (Repeated Measures) analysis for echocardiographic parameters after acute isoproterenol administration to male and female C57Bl/6NCrl mice.

(DOCX)

###### 

Click here for additional data file.

###### Two-way ANOVA analysis for echocardiographic parameters after prolonged isoproterenol administration to male and female C57Bl/6NCrl mice.

(DOCX)

###### 

Click here for additional data file.

###### Two-way ANOVA analysis for hypertrophic and fibrotic markers expression after *prolonged* isoproterenol administration to male and female C57Bl/6NCrl mice.

(DOCX)

###### 

Click here for additional data file.

###### Two-way ANOVA (Repeated Measures) analysis for echocardiographic parameters after prolonged isoproterenol administration to castrated and sham-operated male C57Bl/6NCrl mice.

(DOCX)

###### 

Click here for additional data file.

###### Two-way ANOVA (Repeated Measures) analysis for echocardiographic parameters after prolonged isoproterenol administration to ovariectomized and sham-operated female C57Bl/6NCrl mice.

(DOCX)

###### 

Click here for additional data file.

Experiments using the NanoDrop 8000, ABI 7900 HT, and Agilent 2100 Bioanalyzer were done with staff support at the University of Minnesota Genomics Center. Experiments using the Vevo 2100 echocardiography system were done with staff support at the University of Minnesota Imaging Center. Processing of heart tissues for histopathological analysis was performed with staff support at the Comparative Pathology Shared Resource, University of Minnesota Masonic Cancer Center.
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1\. In your Methods, please provide full details of animal care and housing, including details of the monitoring of the animals for adverse clinical signs.

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Intention of the study was to explore sex differences in heart function and selected myocardial parameters in the response to acute and prolonged isoproterenol stimulation in C57Bl/6 mice. Findings of the study provide clear message for the readers. However, there are some weak points that should be addressed, in particular those dealing with model and interpretation of the results. Therefore, comments should be taken in mind and revision should be done prior consideration for publication.

Title: In general, title should be informative pointing out the main findings of the study.

Abstract: 14 days of isoproterenol administration cannot be considered as chronic adrenergic stimulation but perhaps prolonged stimulation. Age of the animals should be included when looking for sex differences.

Short Title: This title is not adequate because the study did not show any sex difference.

Key words: Instead sex differences "male and female mice" are more relevant key words.

Introduction: There is no doubts that there are sex-related and age-dependent differences in incidence of CVD and heart failure in human population as shown by national registry based information as well as by numerous studies. The issue is, however, very complex and cannot be simplify by selecting some examples without explanations. Therefore, it would be worthwhile to know why there were no sex-related differences in studies you have cited. Which factors appears to play a role in addition to sex hormones.

You noted that sexual dimorphism in cardiovascular diseases is complex and context-dependent. What does mean context-dependent?

Having proper background, you can hypothesize and test your hypothesis. What should imitate your mice model? What was the reason for selected dosing of isoproterenol and duration of application?

Methods: Do you think that a single dose 10 mg/kg of isoproterenol may induce cardiac dysfunction in mice? Maybe higher dose would be more appropriate when examining sex differences. Moreover, as you know rodents are quite resistant to drugs mostly due to high metabolic rate (related also to high heart rate comparing to other species) Some studies did use higher dose do examine extent of ISO-induced injury, e.g. Wallner 2017.

Do you think that mice model is relevant to imitate clinical condition when taking into consideration that there were no differences between males and females controls in your registered parameters?

Results: It is appreciated using thoracic echo examination to detect heart function in mice. How about accuracy of heart function changes in such small animals?

Discussion should be revised to use more proper explanation of the findings and to note limitations of the study.

Conclusions: The findings of the current study can hardly be translating to humans. Moreover, the study did not use severe pathologic stimulus (according to changes in histology, heart function, etc). Therefore, following sentence is not adequate. This study suggests that female sex may not be sufficient to protect the heart against a severe pathologic stimulus, which may explain why women are susceptible to Takotsubo cardiomyopathy.

Reviewer \#2: Overview and general recommendation:

Sex differences in cardiovascular disease has been observed in clinical medicine, as well as within various animal models of cardiac disease. The exact manifestation of these differences varies considerably between species and models. This study investigated the sex differences in a model of excessive catecholamine-induced cardiovascular disease disease by administration of moderate (10 mg/kg) dose isoproterenol subcutaneously to male and female mice. Additionally, the role of sex hormones in this model was further investigated by use of gonadectomized male and female mice. Echocardiographic parameters, histopathology of myocardial tissue, and gene expression of fibrotic markers were assessed.

Overall, this paper is well-written and clear, and the conclusions drawn appear appropriate based on the data provided. The authors discuss the relation between their findings and a multitude of other published studies investigating the role of sex in models of cardiovascular disease in laboratory rodents. The authors are honest about the shortcomings of the second arm of the study regarding gonadectomized animals and do not seek to draw substantial conclusions from this data.

2.1 BROAD COMMENTS

Methods: It would be helpful to clarify the amount of time that has passed from gonadectomy to use in this study for the altered mice. This will alleviate any concerns regarding an incomplete washout period, where residual sex hormones may still be circulating.

Discussion: It is my opinion that a brief discussion of the variables that were of significant difference between sexes (CO in the acute phase, LV mass and HW/TL ratio in the chronic phase), and why these differences still allow the author to draw the conclusion that this model lacks significant sex-related differences, would strengthen the authors position. These items are currently left out of the discussion, and may leave readers wondering if these factors are being intentionally ignored.

2.2 SPECIFIC COMMENTS

Line 63: It would be helpful to characterize the class of pharmacologic agent.

Line 64: Recommend clarifying that this is used to induce cardiac pathologies in laboratory animal models.

Line 81: Recommend providing the exact strain name at least in the Methods section (C57BL/6NCrl)

Line 106: Specify the type of trichrome stain

Line 210: Recommend adding "animals" after the last "sham" of this sentence.

Line 221: Either replace "ISO" with isoproterenol or introduce this abbreviation earlier

Line 246-248: The wording of this sentence is such that it seems to say that you have found sex-related differences, when your conclusion is in fact the opposite. Instead of determined, consider "investigated", or similar terminology to clarify that you were looking in to the possibility of these differences, not that they were determined.

Figure 6: Suggest matching the language between the legend (CAST) and figure itself (CASTRATED)
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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8 Jun 2020

Response to Reviewers:

We would like to thank the editor and reviewers for their time and effort in reviewing our first submission and for providing their valuable comments which have improved the quality and clarity of the manuscript. Please find the following detailed response to the raised concerns.

Editor's Comments:

1\. In your Methods, please provide full details of animal care and housing, including details of the monitoring of the animals for adverse clinical signs.

Response: We would like to thank the editor for this recommendation. We have updated the Methods section in the revised manuscript to include the requested details. Please find lines 94 105 in the revised manuscript.

"Intact male (n=19) and female (n=19) C57Bl/6NCrl mice were purchased from Charles River Laboratories (Protocol ID: 1807-36187A). All mice were housed in groups of 3 - 4 mice per cage and maintained under standard specific pathogen free (SPF) conditions. Mice were given food and water ad libitum in a 12 h light/12 h dark cycle at 21 ± 2 °C. Starting at 15 weeks of age, 10 mg/kg isoproterenol (n=12 male, n=12 female) or an equivalent volume of sterile saline (n=7 male, n=7 female) was administered by subcutaneous daily injection for 14 days. Age-matched mice that had been castrated (n=4), ovariectomized (n=4), or sham-operated (n=4 male, n=4 female) by Charles River Laboratories at the age of 4 weeks were subjected to the isoproterenol regimen described above. Mice were monitored for 30 minutes after each isoproterenol injection, and once daily during the prolonged administration to make sure that this dosage regimen is well tolerated. No mortality or significant morbidity were observed in all experimental groups".

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response: The captions for the Supporting Information have been added to the revised manuscript. Please find lines 632 -- 646.

 

Reviewer \#1: Intention of the study was to explore sex differences in heart function and selected myocardial parameters in the response to acute and prolonged isoproterenol stimulation in C57Bl/6 mice. Findings of the study provide clear message for the readers. However, there are some weak points that should be addressed, in particular those dealing with model and interpretation of the results. Therefore, comments should be taken in mind and revision should be done prior consideration for publication.

Title: In general, title should be informative pointing out the main findings of the study.

Response: We would like to thank the reviewer for this suggestion. We agree with the reviewer about the importance of an informative title. The title of the revised manuscript has been changed to a more informative one. The title now reads: Lack of Sexual Dimorphism in a Mouse Model of Isoproterenol-induced Cardiac Dysfunction.

Abstract: 14 days of isoproterenol administration cannot be considered as chronic adrenergic stimulation but perhaps prolonged stimulation.

Response: We agree with the reviewer that the word "prolonged" better describes our isoproterenol dosage regimen. The word "chronic" has been changed to "prolonged" in the abstract (line 21) and all over the manuscript (please refer to the marked copy of the revised manuscript).

Age of the animals should be included when looking for sex differences.

Response: We would like to thank the reviewer for this important suggestion. The age of mice is now mentioned in the abstract (line 24).

Short Title: This title is not adequate because the study did not show any sex difference.

Response: We agree with the reviewer about this point. The short title has been changed to "Lack of Sex Differences in Cardiac Dysfunction".

Key words: Instead sex differences "male and female mice" are more relevant key words.

Response: We agree with the reviewer about this pint. The key words have been changed to: Sex; male and female; Isoproterenol; Cardiac Dysfunction; Cardiac Hypertrophy

Introduction: There is no doubts that there are sex-related and age-dependent differences in incidence of CVD and heart failure in human population as shown by national registry based information as well as by numerous studies. The issue is, however, very complex and cannot be simplify by selecting some examples without explanations. Therefore, it would be worthwhile to know why there were no sex-related differences in studies you have cited. Which factors appears to play a role in addition to sex hormones.

Response: We would like to thank the reviewer for giving us the opportunity to expand on the introduction section of this manuscript. In the revised version, we have re-written the introduction to elaborate more on the referenced studies. Since the sex-related differences in cardiovascular diseases are complex and cannot be adequately covered in the limited space of the Introduction section, we have also cited important references that provide detailed discussions in this area.

Please refer to lines 55 -- 60

For instance, despite similar overall risk of heart failure between men and women, heart failure with reduced ejection fraction (HFrEF) is more prevalent in men, while heart failure with preserved ejection fraction (HFpEF) is more prevalent in women \[6, 7\]. Although the rationale for the higher prevalence of these specific conditions in women is still not fully understood, coronary microvascular dysfunction and endothelial inflammation have been suggested to play key roles \[6\].

And lines 64 -- 74

Although this traditional view has offered the biological underpinning for several cardiovascular pathologies that are more prevalent and more severe in males \[8, 9\], it could not explain other clinical and preclinical observations including: the worse outcome of post-menopausal women receiving supplemental estrogen therapy which was mainly attributed to increased rate of thromboembolic events \[10\], in addition to post-ischemic cardioprotection in aromatase knock-out mice \[11\] and worsening of heart failure in castrated male experimental animals \[12, 13\] which suggest a cardioprotective role of androgens. In addition to sex hormones, recent studies suggest that inherent differences in sex chromosome genes may contribute to sex differences in cardiovascular diseases \[14\].These studies, among others, strongly suggest that sexual dimorphism in cardiovascular diseases is highly complex in humans (reviewed in \[6, 8, 14-16\]) and thus warrants further investigations in a variety of models in laboratory animals.

You noted that sexual dimorphism in cardiovascular diseases is complex and context-dependent. What does mean context-dependent?

Response: We agree with the reviewer that the word "context-dependent" is vague, so we have changed it in the revised manuscript to "model-dependent".

Please find lines 19 -- 20 in the abstract: Sex-related differences in cardiovascular diseases are highly complex in humans and model-dependent in experimental laboratory animals.

Having proper background, you can hypothesize and test your hypothesis. What should imitate your mice model? What was the reason for selected dosing of isoproterenol and duration of application?

Response: We would like to thank the reviewer for these suggestions. Previous sex differences studies used lower isoproterenol doses that did not cause cardiac dysfunction. Therefore, we initiated this project as an exploratory project, not hypothesis driven. According to the reviewer's suggestion, we explained the rationale behind the selected isoproterenol dosage regimen in the Discussion section of the revised manuscript.

Please refer to lines 272 -- 275

We selected a moderate dose of isoproterenol (10 mg/kg/day) in our current study because sex-related differences in the response to the low dose have been previously determined \[17, 18\] and we expected the high dose to cause severe injury that would mask any potential sex-related difference.

Methods: Do you think that a single dose 10 mg/kg of isoproterenol may induce cardiac dysfunction in mice? Maybe higher dose would be more appropriate when examining sex differences. Moreover, as you know rodents are quite resistant to drugs mostly due to high metabolic rate (related also to high heart rate comparing to other species) Some studies did use higher dose do examine extent of ISO-induced injury, e.g. Wallner 2017.

Response: We would like to thank the reviewer for raising up this point. The rationale for the acute isoproterenol administration was not clear in the first submission. We are aware that a single injection of isoproterenol at 10 mg/kg will not cause immediate cardiac dysfunction. Our intention was to determine whether there is a sex difference in the positive inotropic and chronotropic effects of isoproterenol. This rationale is better explained in the revised manuscript.

Please refer to lines 110 -- 113 in the Methods section:

Cardiac function was assessed by echocardiography prior to isoproterenol administration and immediately following the first dose to determine whether there is a sex difference in the inotropic or chronotropic response to acute isoproterenol administration (n=6 per sex).

And lines 277 -- 281 in the Discussion section:

After acute administration of isoproterenol, we found out that there was a similar increase in cardiac function parameters such as ejection fraction and fractional shortening as well as a similar increase in heart rates in both male and female mice, indicating similar inotropic and chronotropic effects of isoproterenol in male and female mice.

Do you think that mice model is relevant to imitate clinical condition when taking into consideration that there were no differences between males and females controls in your registered parameters?

Response: We would like to thank the reviewer for this comment. Indeed, we found differences in baseline cardiac morphometry between male and female mice, in agreement with human studies. However, there was no significant difference in the response to isoproterenol. These baseline differences are now better articulated in the revision.

Please refer to lines 200 -- 201 in the Results

Female mice had significantly smaller hearts than male mice from the same treatment group (Fig. 2G-H).

And lines 290 -- 291 in the Discussion

In agreement with human studies \[39, 40\], the LV mass, the heart weight, and absolute cardiac output values were lower in female than in male mice.

Results: It is appreciated using thoracic echo examination to detect heart function in mice. How about accuracy of heart function changes in such small animals?

Response: We recognize that trans-thoracic echocardiography in small animals is not an easy job. In this study, echocardiography has been performed by the first author who is well trained on small animal echocardiography and has performed more than 400 echocardiography measurements on mice. This method has accurately measured the changes in LV function in mice showing an increase in EF upon acute adrenergic stimulation a reduction in EF upon prolonged administration. The results of LV mass are corroborated by the heart weight data obtained after necropsy.

Discussion should be revised to use more proper explanation of the findings and to note limitations of the study.

Response: We would like to thank the reviewer for this comment. The Discussion has been updated in the revised manuscript to discuss study limitations.

Please refer to lines 318 -- 323

Although we did not observe significant differences in these key echocardiographic, histopathologic, and molecular markers of cardiac dysfunction, there may be sex-related differences in the molecular pathways leading to such outcome. This notion is supported by a recent study revealing sex-specific differences in cardiac proteomic and metabolomic profiles between men and women with a similar degree of human heart failure \[46\] and thus warrants further investigation.

And lines 345 -- 350

Although the results of these gonadectomy experiments corroborated our previous findings in intact animals, the small sample size and the lack of saline-treated control mice are limitations to the current work. Therefore, future studies are planned to specifically determine the effects of gonadectomy on isoproterenol-induced cardiac dysfunction and remodeling and to identify the molecular determinants of these effects.

Conclusions: The findings of the current study can hardly be translating to humans. Moreover, the study did not use severe pathologic stimulus (according to changes in histology, heart function, etc). Therefore, following sentence is not adequate. This study suggests that female sex may not be sufficient to protect the heart against a severe pathologic stimulus, which may explain why women are susceptible to Takotsubo cardiomyopathy.

Response: We agree with the reviewer that these sentences in the Conclusion may not be the best to reflect our findings. Therefore, we have changed these sentences in the Conclusion to read: "This study suggests that female sex may not be sufficient to protect the heart in this model of isoproterenol-induced cardiac dysfunction. It also signifies the notion that sexual dimorphism in cardiovascular diseases is complex and highly model-dependent" (lines 356 -358).

Regarding the translatability of the findings, experimental laboratory animals have been extensively used to study sex-related differences in cardiovascular diseases. Although there is no perfect animal model that can faithfully mirror a specific human disease, using a variety of models will provide valuable information about the biological basis of these diseases.

Reviewer \#2: Overview and general recommendation:

Sex differences in cardiovascular disease has been observed in clinical medicine, as well as within various animal models of cardiac disease. The exact manifestation of these differences varies considerably between species and models. This study investigated the sex differences in a model of excessive catecholamine-induced cardiovascular disease disease by administration of moderate (10 mg/kg) dose isoproterenol subcutaneously to male and female mice. Additionally, the role of sex hormones in this model was further investigated by use of gonadectomized male and female mice. Echocardiographic parameters, histopathology of myocardial tissue, and gene expression of fibrotic markers were assessed.

Overall, this paper is well-written and clear, and the conclusions drawn appear appropriate based on the data provided. The authors discuss the relation between their findings and a multitude of other published studies investigating the role of sex in models of cardiovascular disease in laboratory rodents. The authors are honest about the shortcomings of the second arm of the study regarding gonadectomized animals and do not seek to draw substantial conclusions from this data.

2.1 BROAD COMMENTS

Methods: It would be helpful to clarify the amount of time that has passed from gonadectomy to use in this study for the altered mice. This will alleviate any concerns regarding an incomplete washout period, where residual sex hormones may still be circulating.

Response: We would like to thank the reviewer for this important comment. Gonadectomy was performed by Charles River Laboratories at the age of 4 weeks to ensure adequate washout period of sex hormones. This information has been added to the revised manuscript (lines 101 -- 102).

Discussion: It is my opinion that a brief discussion of the variables that were of significant difference between sexes (CO in the acute phase, LV mass and HW/TL ratio in the chronic phase), and why these differences still allow the author to draw the conclusion that this model lacks significant sex-related differences, would strengthen the authors position. These items are currently left out of the discussion, and may leave readers wondering if these factors are being intentionally ignored.

Response: We would like to thank the reviewer for this excellent suggestion. We have discussed these parameters in the revised version.

Please refer to lines 290 -- 291

In agreement with human studies \[39, 40\], the LV mass, the heart weight, and absolute cardiac output values were lower in female than in male mice.

2.2 SPECIFIC COMMENTS

Line 63: It would be helpful to characterize the class of pharmacologic agent.

Response: Lines 75 -- 76 now read: "Isoproterenol is non-selective beta-adrenergic agonist commonly used as a pharmacological agent to induce a spectrum of cardiac pathologies in laboratory animal models".

Line 64: Recommend clarifying that this is used to induce cardiac pathologies in laboratory animal models.

Response: Lines 75 -- 76 now read: "Isoproterenol is non-selective beta-adrenergic agonist commonly used as a pharmacological agent to induce a spectrum of cardiac pathologies in laboratory animal models".

Line 81: Recommend providing the exact strain name at least in the Methods section (C57BL/6NCrl)

Response: We would like to thank the reviewer for this excellent suggestion, since there are important differences between the C57Bl/6J and the C57Bl/6NCrl strains of mice. In the revised submission, we have changed all C57Bl/6 mentions to C57Bl/6NCrl. Please refer to the marked copy of the revised submission.

Line 106: Specify the type of trichrome stain

Response: We specified that we used Masson's trichrome stain. Please refer to the Histopathology section in the revised submission.

Line 210: Recommend adding "animals" after the last "sham" of this sentence.

Response: This is corrected in the revised submission (line 234 in the revised submission)

Line 221: Either replace "ISO" with isoproterenol or introduce this abbreviation earlier

Response: This is corrected in the revised submission (line 245 in the revised submission)

Line 246-248: The wording of this sentence is such that it seems to say that you have found sex-related differences, when your conclusion is in fact the opposite. Instead of determined, consider "investigated", or similar terminology to clarify that you were looking in to the possibility of these differences, not that they were determined.

Response: We would like to thank the reviewer for this excellent comment. In the revised submission, we have changed "determined" to "investigated" all over the manuscript. Please refer to the marked copy of the revised submission (multiple occurrences).

Figure 6: Suggest matching the language between the legend (CAST) and figure itself (CASTRATED)

Response: Corrected with thanks.
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Lack of Sexual Dimorphism in a Mouse Model of Isoproterenol-induced Cardiac Dysfunction

PLOS ONE

Dear Dr. Zordoky,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: minor issues are required

==============================

Please submit your revised manuscript by Aug 07 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thanks for your valuable responses that for sure improved the understanding and message of your study.

Reviewer \#2: Ms. Ref. No.: PONE-D-20-10894

Title: Isoproterenol-induced Cardiac Dysfunction in Male and Female C57Bl/6 Mice

Grant, Abdelgawad, Lewis, Seelig, and Zordoky

Overview and general recommendation:

The authors have thoroughly addressed this reviewer's concerns, and the paper is well written and draws valid conclusions.

SPECIFIC COMMENTS

Line 131 -- 133: The scale for histopathology currently reads, "0, absent; 1, minimal inflammation or fibrosis; 2, mild minimal inflammation or fibrosis; 3, moderate minimal inflammation or fibrosis; and 4, marked minimal inflammation or fibrosis.". Is the word "minimal" in 2, 3, and 4 an error?
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232507.r004

Author response to Decision Letter 1

23 Jun 2020

We would like to thank the editor and reviewers for their time and effort in reviewing our first submission and for providing their valuable comments which have improved the quality and clarity of the manuscript. Please find the following detailed response to the raised concerns.

Reviewer \#1: Thanks for your valuable responses that for sure improved the understanding and message of your study.

Response: We are truly appreciative to the reviewer for their comments.

Reviewer \#2:

Overview and general recommendation:

The authors have thoroughly addressed this reviewer's concerns, and the paper is well written and draws valid conclusions.

Response: We are truly appreciative to the reviewer for their comments.

SPECIFIC COMMENTS

Line 131 -- 133: The scale for histopathology currently reads, "0, absent; 1, minimal inflammation or fibrosis; 2, mild minimal inflammation or fibrosis; 3, moderate minimal inflammation or fibrosis; and 4, marked minimal inflammation or fibrosis.". Is the word "minimal" in 2, 3, and 4 an error?

Response: We would like to thank the reviewer for catching this typographical error. The word "minimal" in 2, 3, and 4 was an error and omitted in the revised submission.

Lines 130 -- 133 now read: "Inflammation and fibrosis were assessed as follows: 0, absent; 1, minimal inflammation or fibrosis; 2, mild inflammation or fibrosis; 3, moderate inflammation or fibrosis; and 4, marked inflammation or fibrosis".

###### 

Submitted filename: PLOS One Response to Reviewers_R2.docx

###### 

Click here for additional data file.
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

25 Jun 2020

Lack of Sexual Dimorphism in a Mouse Model of Isoproterenol-induced Cardiac Dysfunction

PONE-D-20-10894R2

Dear Dr. Zordoky,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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29 Jun 2020

PONE-D-20-10894R2

Lack of Sexual Dimorphism in a Mouse Model of Isoproterenol-induced Cardiac Dysfunction

Dear Dr. Zordoky:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Vincenzo Lionetti

Academic Editor

PLOS ONE
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